STATEMENT OF NEED
Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Nonmetastatic CRPC is a highly heterogeneous disease process with a dearth of effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 31,620 deaths annually. Median overall survival remains less than 2 years.
Oncology and urology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC).
Upon completion of this activity, participants should be able to:
Brenda Martone, MSN, ANP-BC, AOCNP® (Chairperson)
Kathleen Burns, NP
City of Hope
Theresa W. Gillespie, PhD, MA, RN, FAAN
Professor, Department of Surgery and Department of Hematology & Medical Oncology
Emory University School of Medicine
There is no fee to participate in or claim CNE credit for this activity.
Continuing Nursing Education
i3 Health is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity. This activity has been approved for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN®renewal candidates may apply 1 ILNA point toward:
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of a CNE activity to disclose all financial relationships with commercial interests that are related to the content of the CNE activity. CNE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CNE content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
Brenda Martone, MSN, ANP-BC, AOCNP®, discloses that she has served on the speakers' bureau for Astellas and Pfizer.
Kathleen Burns, NP, discloses that she has served on the advisory board for Pfizer. Ms. Burns has also served on the speakers' bureau for Amgen, Astellas, Bristol-Myers Squibb, Merck, and Pfizer.
Theresa W. Gillespie, PhD, MA, RN, FAAN has no commercial relationships to disclose.
The i3 Health planners and managers have nothing to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CNE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CNE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by independent educational grants from Bayer Healthcare Pharmaceuticals and Sanofi Genzyme.
Aggregate participant data will be shared with commercial supporters of this activity.
AMERICANS WITH DISABILITIES ACT